Davis, California, USA
November 21, 2014

Marrone Bio Innovations, Inc. (MBI) (NASDAQ:MBII) today announced that, as anticipated, it has received a letter from the Listing Qualifications Department of The NASDAQ Stock Market LLC ("NASDAQ") notifying MBI of its noncompliance with NASDAQ Listing Rule 5250(c)(1) as a result of the company's filing of a Notification of Late Filing on Form 12b-25 on November 14, 2014. In the Form 12b-25, the company indicated that the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (the "Form 10-Q") will be delayed until after the completion of the previously-disclosed internal investigation by the Company's Audit Committee regarding certain accounting matters.

The NASDAQ letter notes that the Company is required to submit a plan to regain compliance with NASDAQ's filing requirements for continued listing within 60 calendar days of the date of the NASDAQ notification letter. Upon acceptance of the Company's compliance plan, NASDAQ is permitted to grant an extension of up to 180 days from the Form 10-Q's filing due date for the Company to regain compliance with NASDAQ's filing requirements for continued listing.

The Company's Audit Committee continues to work diligently to complete its internal investigation, and the Company intends to regain compliance with the NASDAQ's filing requirements. The Company intends to file the Form 10-Q as soon as practicable after the Audit Committee completes its investigation. At this time, the Company is not able to provide an estimate of when the investigation will be completed or when such filing will be made. 

Website: http://marronebioinnovations.com/

Published: November 21, 2014